Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.

CONCLUSION: Concomitant BEV effectively reduces treatment toxicity of reRT and should be reconsidered in future reRT protocols.
PMID: 31252301 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - June 24, 2019 Category: Radiology Authors: Fleischmann DF, Jenn J, Corradini S, Ruf V, Herms J, Forbrig R, Unterrainer M, Thon N, Kreth FW, Belka C, Niyazi M Tags: Radiother Oncol Source Type: research